This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented): A compound of formula I



I

in which

R^1 is Hal, NO_2, CF_3, COOH, COOR or H,

R^2 is R, Hal, CN, NO_2, NHR, NRR, NHCOR, $NHSO_2R$, OR, CO-R, CO-NHR, CF_3, OCF_3, SCF_3, SO_3R, SO_2R, SO_2NR, SR, COOH or COOR,

R^3 is Hal or CO-NHR,

R is H or unsubstituted or mono-, di-, tri- or tetra-R^4-substituted A, Ar, Het, $(CH_2)_qHet$ or $(CH_2)_qAr$,

A is unbranched, branched or cyclic alkyl having 1-14 C atoms, in which one or two CH_2 groups are each optionally replaced by O, S, or -CH=CH- and/or 1-7 H atoms are each optionally replaced by F or Cl,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, OH, OA, CN, NO_2, NH_2, NHA, NA_2, NHCOA, SCF_3, SO_2A, COOH, COOA, $CONH_2$, CONHA, $CONA_2$, $NHSO_2A$, SO_2NH_2, SO_2NHA, SO_2NA_2, CHO or COA,

Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, Hal, A, $-(CH_2)_b$-Ar, $-(CH_2)_b$-cycloalkyl, OH, OA, NH_2, NHA, NA_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CONA_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2 and/or $S(O)_gA$,

Hal is F, Cl, Br or I,

R^4 is Hal, OH, CN, NO_2, CF_3, OCF_3, SCF_3, SO_2A or OA,

X is O, S, ~~SO_2NH~~ or NH,

Ⓨ is phenyl or a monocyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,

b is 0, 1, 2, 3 or 4,

g is 0, 1 or 2,

n, m, p, q are each, independently of one another, 1, 2, 3, or 4,

or a pharmaceutically acceptable salt, or stereoisomer thereof, including mixtures of stereoisomers in all ratios.

2. (Cancelled):

3. (Previously Presented): A compound according to Claim 1, in which R^2 is H.

4. (Cancelled):

5. (Previously Presented): A compound according to claim 1, in which Ⓨ is phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl.

6. (Currently Amended): A compound according to Claim 1, in which

R^2 is H,

Ⓨ is phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl,

X is O, S, ~~SO_2NH~~ or NH,

n, p, are each, independently of one another, 1, 2, 3 or 4,

m is 1.

7. (Previously Presented): A compound selected from:
benzoxazol-2-yl-[4-(pyridin-4-yloxy)phenyl]amine,
benzoxazol-2-yl-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
N-benzoxazol-2-yl-N'-pyridin-4-ylbenzene-1,4-diamine,
2-[4-(pyridin-4-ylsulfanyl)phenylamino]benzoxazole-5-carboxylic acid,

2-[4-(pyridin-4-yloxy)phenylamino]benzoxazole-6-carboxylic acid,
2-[4-(pyridin-4-ylsulfanyl)phenylamino]benzoxazole-6-carboxylic acid,
methyl 2-[4-(pyridin-4-ylamino)phenylamino]benzoxazole-6-carboxylate,
(5-nitrobenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
(5-nitrobenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,
N-(5-nitrobenzoxazol-2-yl)-N'-pyridin-4-ylbenzene-1,4-diamine,
(6-nitrobenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,
(6-nitrobenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
N-(6-nitrobenzoxazol-2-yl)-N'-pyridin-4-ylbenzene-1,4-diamine,
(5-chloro-7-nitrobenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,
(5-chloro-7-nitrobenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
N-(5-chloro-7-nitrobenzoxazol-2-yl)-N'-pyridin-4-ylbenzene-1,4-diamine,
(7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]-amine,
(7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]-amine,
(7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(4-fluorophenylsulfanyl)-phenyl]amine,
N-[4-(bromotrifluoromethylbenzoxazol-2-ylamino)phenyl]-4-fluoro-benzenesulfonamide,
[4-(2-amino-6-methylpyrimidin-4-yloxy)phenyl]-(7-bromo-5-trifluoro-methylbenzoxazol-2-yl)amine,
N-methyl-4-[4-(bromotrifluoromethylbenzoxazol-2-ylamino)phenoxy]-pyridine-2-carboxamide,
N-methyl-4-[4-(bromotrifluoromethylbenzoxazol-2-ylamino)phenylsulfanyl]-pyridine-2-carboxamide, and
(7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(2,4-difluorophenylsulfanyl)-phenyl]amine,

and pharmaceutically acceptable salts, and stereoisomers thereof, including mixtures of stereoisomers in all ratios.

8 (Previously Presented): A process for preparation of a compound according to claim 1, said process comprising:

reacting a compound of formula II



II

with a compound of formula III



III .

9. (Previously Presented): A pharmaceutical composition comprising at least one compound according to claim 1 and one or more excipients and/or adjuvants.

10. (Previously Presented): A pharmaceutical composition comprising at least one compound according to claim 1, and at least one further medicament active ingredient.

11. (Previously Presented): A kit consisting of separate packs of

a) an effective amount of a compound according to claim 1, and

b) an effective amount of a further medicament active ingredient.

12. (Cancelled):

13. (Cancelled):

Claims 14 - 29. (Cancelled):

30. (Previously Presented): A compound according to claim 1, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, linear or branched heptyl, octyl, nonyl, decyl, trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.

31. (Previously Presented): A compound according to claim 30, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl.

32. (Previously Presented): A compound according to claim 30, wherein A is alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which one or two CH_2 groups are each optionally replaced by O, S, or by -CH=CH-, and 1-7 H are each optionally replaced by F or Cl.

33. (Previously Presented): A compound according to claim 30, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl, or 1,1,1-trifluoroethyl.

34. (Previously Presented): A compound according to claim 1, wherein Ar is phenyl, naphthyl or biphenyl, which in each case is mono-, di- or trisubstituted by substituents selected from A, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, nitro, cyano, formyl, acetyl, propionyl, trifluoromethyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, benzyloxy, sulfonamido, methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, dimethylsulfonamido, phenylsulfonamido, carboxyl, methoxycarbonyl, ethoxycarbonyl, and aminocarbonyl.

35. (Previously Presented): A compound according to claim 1, wherein Het is 2-

or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, furthermore preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl, or 2,1,3-benzoxadiazol-5-yl, which in each case is unsubstituted or mono-, di- or trisubstituted by substituents selected from carbonyl oxygen, F, Cl, Br, methyl, ethyl, propyl, phenyl, benzyl, -CH_2-cyclohexyl, hydroxyl, methoxy, ethoxy, amino, methylamino, dimethylamino, nitro, cyano, carboxyl, methoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, acetamino, ureido, methylsulfonylamino, formyl, acetyl, aminosulfonyl, and methylsulfonyl, or

Het is 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-,-2-,-3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro-2H-benzo-1,4-oxazinyl, furthermore preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl, 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-yl, 2,3-

dihydrobenzofuranyl , 2,3-dihydro-2-oxofuranyl, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl, 2-hydroxy-6-oxopiperazin-1-yl, 2-methoxy-6-oxopiperazin-1-yl, or 2-azabicyclo[2.2.2]octan-3-on-2-yl.

36. (Previously Presented): A compound according to claim 1, wherein is phenyl, pyridyl or pyrimidinyl.

37. (Previously Presented): A compound according to claim 35, wherein

A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, linear or branched heptyl, octyl, nonyl, decyl, trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; and

Ar is phenyl, naphthyl or biphenyl, which in each case is mono-, di- or trisubstituted by substituents selected from A, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, nitro, cyano, formyl, acetyl, propionyl, trifluoromethyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, benzyloxy, sulfonamido, methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, dimethylsulfonamido, phenylsulfonamido, carboxyl, methoxycarbonyl, ethoxycarbonyl, and aminocarbonyl.

38. (Currently Amended): A compound according to Claim 1, in which

R^1 is Hal, NO_2, CF_3, COOH, COOR or H,

R^2 is H,

Y is phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl, and

X is O, S, ~~SO_2NH~~ or NH.